Abstract: Objective To discuss the factors associated with adverse reactions caused by platelet transfusions in patients with tumors. Methods A retrospective analysis of adverse reactions in tumor patients receiving platelet transfusions in a hospital between January and December 2018 was done. Patients were divided into adverse reaction group and non-adverse reaction group. Univariate analyses were conducted to assess the factors in the two groups, such as age, sex, ethnicity, blood type, history of pregnancy, history of blood transfusion, clinical diagnosis, platelet transfusion dosing, platelet storage time, platelet transfusion times and compatible platelet transfusions etc.. Logistic regression analysis was conducted to analyze the independent risk factors affecting adverse reactions during platelet transfusion. Results A total of 1 086 patients receiving platelet transfusions were included in the study. The rate of adverse reactions to transfusion was 6.72% (73/1 086), including 36 patients with non-hemolytic fever and 37 patients with anaphylaxis. There were statistically significant differences between the two groups in transfusion history, platelet storage period, platelet transfusion times and HLA/HPA-matched platelet transfusions (P<0.05). Multivariate regression showed HLA/HPA-unmatched platelet transfusions (random transfusions)（OR=2.113,95%CI:1.282~3.482,P=0.003）was an independent risk factor for adverse reactions to platelet transfusion. Conclusion HLA/HPA-matched platelet transfusions can reduce the incidence of adverse transfusion reactions in tumor patients.

Key words: Tumor patients, Platelet transfusion, Adverse reaction, Influence factors